Th17 polarization of memory Th cells in early arthritis: The vasoactive intestinal peptide effect

Journal of Leukocyte Biology

Volumn 98, Issue 2, 2015, Pages 257-269

  Jimeno, Rebeca ^a   Leceta, Javier ^a   Garín, Marina ^b   Ortiz, Ana M ^c   Mellado, Mario ^d   Rodríguez Frade, Jose Miguel ^d   Martínez, Carmen ^a   Pérez García, Selene ^a   Gomariz, Rosa P ^a   Juarranz, Yasmina ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b CIEMAT   (Spain)

^c HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^d CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

Autoimmune diseases; VIP; VPAC receptors

Indexed keywords

CD45RO ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 22; INTERLEUKIN 9; TRANSCRIPTION FACTOR FOXP3; VASOACTIVE INTESTINAL POLYPEPTIDE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; IL17A PROTEIN, HUMAN; IL9 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22; TRANSFORMING GROWTH FACTOR BETA;

ADAPTIVE IMMUNITY; ADULT; ARTICLE; BLOOD; CELL DIFFERENTIATION; CLINICAL ARTICLE; FEMALE; HUMAN; INNATE IMMUNITY; MALE; MEMORY T LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TH17 CELL; ARTHRITIS, RHEUMATOID; BIOSYNTHESIS; CASE CONTROL STUDY; CELL PROLIFERATION; DRUG EFFECTS; EARLY DIAGNOSIS; GENE EXPRESSION; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PRIMARY CELL CULTURE; REGULATORY T LYMPHOCYTE; SECRETION (PROCESS); SIGNAL TRANSDUCTION;

ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; CELL PROLIFERATION; EARLY DIAGNOSIS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; INTERLEUKIN-17; INTERLEUKIN-9; INTERLEUKINS; MALE; MIDDLE AGED; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; TRANSFORMING GROWTH FACTOR BETA; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84938331825     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.3A0714-327R     Document Type: Article

References (54)

1. Machold, K. P., Stamm, T. A., Nell, V. P., Pflugbeil, S., Aletaha, D., Steiner, G., Uffmann, M., Smolen, J. S. (2007) Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) 46, 342–349
2. Hickman-Brecks, C. L., Racz, J. L., Meyer, D. M., LaBranche, T. P., Allen, P. M. (2011) Th17 cells can provide B cell help in autoantibody induced arthritis. J. Autoimmun. 36, 65–75
3. Van den Berg, W. B., Miossec, P. (2009) IL-17 as a future therapeutic target for rheumatoid arthritis. Nat. Rev. Rheumatol. 5, 549–553
4. Kellner, H. (2013) Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential. Ther. Adv. Musculoskelet. Dis. 5, 141–152
5. Leipe, J., Grunke, M., Dechant, C., Reindl, C., Kerzendorf, U., Schulze- Koops, H., Skapenko, A. (2010) Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum. 62, 2876–2885
6. Eggleton, P., Bremer, E., Tarr, J. M., de Bruyn, M., Helfrich, W., Kendall, A., Haigh, R. C., Viner, N. J., Winyard, P. G. (2011) Frequency of Th17 CD20+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects. Arthritis Res. Ther. 13, R208
7. Kim, J., Kang, S., Kim, J., Kwon, G., Koo, S. (2013) Elevated levels of T helper 17 cells are associated with disease activity in patients with rheumatoid arthritis. Ann. Lab. Med. 33, 52–59
8. Benedetti, G., Miossec, P. (2014) Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis. Eur. J. Immunol. 44, 339–347
9. Yang, X. O., Pappu, B. P., Nurieva, R., Akimzhanov, A., Kang, H. S., Chung, Y., Ma, L., Shah, B., Panopoulos, A. D., Schluns, K. S., Watowich, S. S., Tian, Q., Jetten, A. M., Dong, C. (2008) T Helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR a and ROR g. Immunity 28, 29–39
10. Sundrud, M. S., Trivigno, C. (2013) Identity crisis of Th17 cells: many forms, many functions, many questions. Semin. Immunol. 25, 263–272
11. Van Hamburg, J. P., Asmawidjaja, P. S., Davelaar, N., Mus, A. M., Colin, E. M., Hazes, J. M., Dolhain, R. J., Lubberts, E. (2011) Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum. 63, 73–83
12. Korn, T., Bettelli, E., Oukka, M., Kuchroo, V. K. (2009) IL-17 and Th17 cells. Annu. Rev. Immunol. 27, 485–517
13. Lee, Y., Awasthi, A., Yosef, N., Quintana, F. J., Xiao, S., Peters, A., Wu, C., Kleinewietfeld, M., Kunder, S., Hafler, D. A., Sobel, R. A., Regev, A., Kuchroo, V. K. (2012) Induction and molecular signature of pathogenic TH17 cells. Nat. Immunol. 13, 991–999
14. Ghoreschi, K., Laurence, A., Yang, X. P., Tato, C. M., McGeachy, M. J., Konkel, J. E., Ramos, H. L., Wei, L., Davidson, T. S., Bouladoux, N., Grainger, J. R., Chen, Q., Kanno, Y., Watford, W. T., Sun, H. W., Eberl, G., Shevach, E. M., Belkaid, Y., Cua, D. J., Chen, W., O’Shea, J. J. (2010) Generation of pathogenic T(H)17 cells in the absence of TGF-b signalling. Nature 467, 967–971
15. Haines, C. J., Chen, Y., Blumenschein, W. M., Jain, R., Chang, C., Joyce- Shaikh, B., Porth, K., Boniface, K., Mattson, J., Basham, B., Anderton, S. M., McClanahan, T. K., Sadekova, S., Cua, D. J., McGeachy, M. J. (2013) Autoimmune memory T helper 17 cell function and expansion are dependent on interleukin-23. Cell Reports 3, 1378–1388
16. Kleinewietfeld, M., Hafler, D. A. (2013) The plasticity of human Treg and Th17 cells and its role in autoimmunity. Semin. Immunol. 25, 305–312
17. Hoechst, B., Gamrekelashvili, J., Manns, M. P., Greten, T. F., Korangy, F. (2011) Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood 117, 6532–6541
18. Obermajer, N., Popp, F. C., Soeder, Y., Haarer, J., Geissler, E. K., Schlitt, H. J., Dahlke, M. H. (2014) Conversion of Th17 into IL-17A(neg) regulatory T cells: a novel mechanism in prolonged allograft survival promoted by mesenchymal stem cell-supported minimized immunosuppressive therapy. J. Immunol. 193, 4988–4999
19. Gomariz, R. P., Martinez, C., Abad, C., Leceta, J., Delgado, M. (2001) Immunology of VIP: a review and therapeutical perspectives. Curr. Pharm. Des. 7, 89–111
20. Gomariz, R. P., Juarranz, Y., Abad, C., Arranz, A., Leceta, J., Martínez, C. (2006) VIP-PACAP system in immunity: new insights for multitarget therapy. Ann. N. Y. Acad. Sci. 1070, 51–74
21. Dorsam, G. P., Benton, K., Failing, J., Batra, S. (2011) Vasoactive intestinal peptide signaling axis in human leukemia. World J Biol Chem 2, 146–160
22. Delgado, M., Martinez, C., Johnson, M. C., Gomariz, R. P., Ganea, D. (1996) Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J. Neuroimmunol. 68, 27–38
23. Leceta, J., Gomariz, R. P., Martinez, C., Carrión, M., Arranz, A., Juarranz, Y. (2007) Vasoactive intestinal peptide regulates Th17 function in autoimmune inflammation. Neuroimmunomodulation 14, 134–138
24. Jimeno, R., Leceta, J., Martínez, C., Gutiérrez-Cañas, I., Pérez-García, S., Carrión, M., Gomariz, R. P., Juarranz, Y. (2012) Effect of VIP on the balance between cytokines and master regulators of activated helper T cells. Immunol. Cell Biol. 90, 178–186
25. Jimeno, R., Leceta, J., Martínez, C., Gutiérrez-Cañas, I., Carrión, M., Pérez-García, S., Garín, M., Mellado, M., Gomariz, R. P., Juarranz, Y. (2014) Vasoactive intestinal peptide maintains the nonpathogenic profile of human th17-polarized cells. J. Mol. Neurosci. 54, 512–525
26. Yadav, M., Rosenbaum, J., Goetzl, E. J. (2008) Cutting edge: vasoactive intestinal peptide (VIP) induces differentiation of Th17 cells with a distinctive cytokine profile. J. Immunol. 180, 2772–2776
27. Delgado, M., Abad, C., Martinez, C., Leceta, J., Gomariz, R. P. (2001) Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat. Med. 7, 563–568
28. Juarranz, Y., Abad, C., Martinez, C., Arranz, A., Gutierrez-Cañas, I., Rosignoli, F., Gomariz, R. P., Leceta, J. (2005) Protective effect of vasoactive intestinal peptide on bone destruction in the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res. Ther. 7, R1034–R1045
29. Carrión, M., Pérez-García, S., Jimeno, R., Juarranz, Y., González-álvaro, I., Pablos, J. L., Gutiérrez-Cañas, I., Gomariz, R. P. (2013) Inflammatory mediators alter IL-17 receptors, IL-12 and IL-23 expression in human osteoarthritic and rheumatoid arthritis sinovial fibroblast. Immunomodulation by VIP. Neuroimmunomodulation 20, 274–284
30. Gutiérrez-Cañas, I., Juarranz, Y., Santiago, B., Martínez, C., Gomariz, R. P., Pablos, J. L., Leceta, J. (2008) Immunoregulatory properties of vasoactive intestinal peptide in human T cell subsets: implications for rheumatoid arthritis. Brain Behav. Immun. 22, 312–317
31. Juarranz, Y., Guti érrez-Cañas, I., Santiago, B., Carrión, M., Pablos, J. L., Gomariz, R. P. (2008) Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts. Arthritis Rheum. 58, 1086–1095
32. Juarranz, M. G., Santiago, B., Torroba, M., Gutierrez-Cañas, I., Palao, G., Galindo, M., Abad, C., Martinez, C., Leceta, J., Pablos, J. L., Gomariz, R. P. (2004) Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells. Rheumatology (Oxford) 43, 416–422
33. Martínez, C., Ortiz, A. M., Juarranz, Y., Lamana, A., Seoane, I. V., Leceta, J., García-Vicuña, R., Gomariz, R. P., González-Álvaro, I. (2014) Serum levels of vasoactive intestinal peptide as a prognostic marker in early arthritis. PLoS ONE 9, e85248
34. Jimeno, R., Gomariz, R. P., Garín, M., Gutiérrez-Cañas, I., González-Álvaro, I., Carrión, M., Galindo, M., Leceta, J., Juarranz, Y. (2015) The pathogenic Th profile of human activated memory Th cells in early rheumatoid arthritis can be modulated by VIP. J. Mol. Med. (Berl). 93, 457–467
35. Miossec, P., Kolls, J. K. (2012) Targeting IL-17 and TH17 cells in chronic inflammation. Nat. Rev. Drug Discov. 11, 763–776
36. Patel, D. D., Lee, D. M., Kolbinger, F., Antoni, C. (2013) Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann. Rheum. Dis. 72 (Suppl 2), ii116–ii123
37. Aletaha, D., Neogi, T., Silman, A. J., Funovits, J., Felson, D. T., Bingham, C. O., Birnbaum, N. S., Burmester, G. R., Bykerk, V. P., Cohen, M. D., Combe, B., Costenbader, K. H., Dougados, M., Emery, P., Ferraccioli, G., Hazes, J. M., Hobbs, K., Huizinga, T. W., Kavanaugh, A., Kay, J., Kvien, T. K., Laing, T., Mease, P., Ménard, H. A., Moreland, L. W., Naden, R. L., Pincus, T., Smolen, J. S., Stanislawska-Biernat, E., Symmons, D., Tak, P. P., Upchurch, K. S., Vencovský, J., Wolfe, F., Hawker, G. (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62, 2569–2581
38. Lubberts, E., Koenders, M. I., Oppers-Walgreen, B., van den Bersselaar, L., Coenen-de Roo, C. J., Joosten, L. A., van den Berg, W. B. (2004) Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 50, 650–659
39. Omoyinmi, E., Hamaoui, R., Pesenacker, A., Nistala, K., Moncrieffe, H., Ursu, S., Wedderburn, L. R., Woo, P. (2012) Th1 and Th17 cell subpopulations are enriched in the peripheral blood of patients with systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 51, 1881–1886
40. Shen, H., Goodall, J. C., Hill Gaston, J. S. (2009) Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. Arthritis Rheum. 60, 1647–1656
41. McGeachy, M. J., Chen, Y., Tato, C. M., Laurence, A., Joyce-Shaikh, B., Blumenschein, W. M., McClanahan, T. K., O’Shea, J. J., Cua, D. J. (2009) The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat. Immunol. 10, 314–324
42. Lee, Y. K., Turner, H., Maynard, C. L., Oliver, J. R., Chen, D., Elson, C. O., Weaver, C. T. (2009) Late developmental plasticity in the T helper 17 lineage. Immunity 30, 92–107
43. Bending, D., De la Peña, H., Veldhoen, M., Phillips, J. M., Uyttenhove, C., Stockinger, B., Cooke, A. (2009) Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice. J. Clin. Invest. 119, 565–572
44. Mukasa, R., Balasubramani, A., Lee, Y. K., Whitley, S. K., Weaver, B. T., Shibata, Y., Crawford, G. E., Hatton, R. D., Weaver, C. T. (2010) Epigenetic instability of cytokine and transcription factor gene loci underlies plasticity of the T helper 17 cell lineage. Immunity 32, 616–627
45. Gocke, A. R., Cravens, P. D., Ben, L. H., Hussain, R. Z., Northrop, S. C., Racke, M. K., Lovett-Racke, A. E. (2007) T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J. Immunol. 178, 1341–1348
46. Hirota, K., Duarte, J. H., Veldhoen, M., Hornsby, E., Li, Y., Cua, D. J., Ahlfors, H., Wilhelm, C., Tolaini, M., Menzel, U., Garefalaki, A., Potocnik, A. J., Stockinger, B. (2011) Fate mapping of IL-17-producing T cells in inflammatory responses. Nat. Immunol. 12, 255–263
47. Esensten, J. H., Lee, M. R., Glimcher, L. H., Bluestone, J. A. (2009) T-betdeficient NOD mice are protected from diabetes due to defects in both T cell and innate immune system function. J. Immunol. 183, 75–82
48. Komatsu, N., Okamoto, K., Sawa, S., Nakashima, T., Oh-hora, M., Kodama, T., Tanaka, S., Bluestone, J. A., Takayanagi, H. (2014) Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat. Med. 20, 62–68
49. Abad, C., Gomariz, R., Waschek, J., Leceta, J., Martinez, C., Juarranz, Y., Arranz, A. (2012) VIP in inflammatory bowel disease: state of the art. Endocr. Metab. Immune Disord. Drug Targets 12, 316–322
50. Jimeno, R., Gomariz, R. P., Gutiérrez-Cañas, I., Martínez, C., Juarranz, Y., Leceta, J. (2010) New insights into the role of VIP on the ratio of T-cell subsets during the development of autoimmune diabetes. Immunol. Cell Biol. 88, 734–745
51. Ding, W., Manni, M., Stohl, L. L., Zhou, X. K., Wagner, J. A., Granstein, R. D. (2012) Pituitary adenylate cyclase-activating peptide and vasoactive intestinal polypeptide bias Langerhans cell Ag presentation toward Th17. Eur. J. Immunol. 42, 901–911
52. Lara-Marquez, M., O’Dorisio, M., O’Dorisio, T., Shah, M., Karacay, B. (2001) Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells. J. Immunol. 166, 2522–2530
53. Vomhof-DeKrey, E. E., Hermann, R. J., Palmer, M. F., Benton, K. D., Sandy, A. R., Dorsam, S. T., Dorsam, G. P. (2008) TCR signaling and environment affect vasoactive intestinal peptide receptor-1 (VPAC-1) expression in primary mouse CD4 T cells. Brain Behav. Immun. 22, 1032–1040
54. Delgado, M., Robledo, G., Rueda, B., Varela, N., O’Valle, F., Hernández- Cortes, P., Caro, M., Orozco, G., Gonzalez-Rey, E., Martin, J. (2008) Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells. Arthritis Rheum. 58, 1010–1019.